EUVIMEDEUVIMED entdecken
Crossref

High‐throughput screening for prescribing cascades among real world statin initiators

Scott M Vouri iD, Earl J Morris iD, Marta Walsh iD, Jessica Agalliu, Alyssa Dempsey, Leonie Hochleitner, Matthew R Muschett, Stephan Schmidt, Carl J Pepine iD, Steven M Smith iD

Pharmacoepidemiology and Drug Safety · 2023

DOI: 10.1002/pds.5607 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2023. Verfasst von Scott M Vouri und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: UF College of Pharmacy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Statins are among the most prevalent medications prescribed and associated with adverse events that may prompt additional treatment (i.e., a prescribing cascade). No comprehensive assessment of statin‐related prescribing cascades has been performed to our knowledge.

Methods

We utilized sequence symmetry analysis to iteratively screen prescribing sequences of all therapeutic classes (“marker” classes) based on Level 4 Anatomical Therapeutic Chemical codes among adult statin initiators, using IBM Marketscan commercial and Medicare supplemental claims databases (2005–2019). Order of initiation and secular trend‐adjusted sequence ratios were calculated for each statin‐marker class dyad, among marker class initiators ±90 days of statin initiation. Among signals classified as prescribing cascades, we calculated naturalistic number needed to harm (NNTH) within 1 year as the inverse of the excess risk among exposed.

Results

We identified 2 265 519 statin initiators (mean ± SD age, 56.4 ± 12.0 years; 48.7% women; 7.5% with cardiovascular disease). Simvastatin (34.4% of statin initiators) and atorvastatin (33.9%) were the most commonly initiated statins. We identified 160 significant statin‐marker class dyad signals, of which 35.6% ( n = 57) were classified as potential prescribing cascades. Of the top 25 strongest signals (lowest NNTH), 12 were classified as potential prescribing cascades, including osmotically acting laxatives (NNTH, 44, 95% CI 43–46), opioids + non‐opioid combination analgesics (81, 95% CI 74–91), and first‐generation cephalosporins (204, 95% CI 175–246).

Conclusions

Using high‐throughput sequence symmetry analysis screening, we identified previously known prescribing cascades as well as potentially new prescribing cascades based on known and unknown statin‐related adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsAgedAdultHumansFemaleUnited StatesMiddle AgedMaleHigh-Throughput Screening AssaysMedicareSimvastatinAtorvastatin

Stichwörter der Autor:innen

HMG-CoA reductase inhibitorsprescribing cascadesequence symmetry analysisstatins

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsSimvastatinAtorvastatin

Autor:innen und Institutionen

  • Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
  • College of Pharmacy, University of Florida, Gainesville, Florida, USA.
  • Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, Florida, USA.
  • Division of Cardiovascular Medicine, Department of Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA.
  • Center for Integrative Cardiovascular and Metabolic Disease, University of Florida, Gainesville, Florida, USA.

ORCID-Profile: Scott M Vouri, Earl J Morris, Marta Walsh, Carl J Pepine, Steven M Smith

Förderung

  • UF College of Pharmacy

Zitieren

APA

Vouri, S. M., Morris, E. J., Walsh, M., Agalliu, J., Dempsey, A., Hochleitner, L., Muschett, M. R., Schmidt, S., Pepine, C. J., & Smith, S. M. (2023). High‐throughput screening for prescribing cascades among real world statin initiators. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5607

Vancouver

Vouri SM, Morris EJ, Walsh M, Agalliu J, Dempsey A, Hochleitner L, et al. High‐throughput screening for prescribing cascades among real world statin initiators. Pharmacoepidemiology and Drug Safety. 2023. doi:10.1002/pds.5607

BibTeX
@article{Vouri2023,
  author = {Vouri, Scott M and Morris, Earl J and Walsh, Marta and Agalliu, Jessica and Dempsey, Alyssa and Hochleitner, Leonie and Muschett, Matthew R and Schmidt, Stephan and Pepine, Carl J and Smith, Steven M},
  title = {High‐throughput screening for prescribing cascades among real world statin initiators},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2023},
  doi = {10.1002/pds.5607}
}
Kostenlos starten →